Recent studies have revealed that CBX1 was upregulated in HCC, castration-resistant prostate cancer and breast cancer, and a high expression of CBX1 predicted worse survival outcomes in HCC and shorter recurrence-free survival in BC patients [17,18,37]. Here, CBX1 is linked to breast cancer.